Gossamer Bio, Inc. (GOSS) shares collapsed 81.56 percent to $0.3929, down $1.7371 on Monday, after the company reported topline results from its Phase 3 PROSERA study of seralutinib in pulmonary arterial hypertension that narrowly missed the prespecified statistical threshold for the primary endpoint.
The stock is currently trading at $0.3929, compared with a previous close of $2.1300 Nasdaq. It opened sharply lower at $0.5969 and has traded between $0.4026 and $0.6000 during the session. Trading volume has surged to 80.56 million shares, far exceeding its average volume of 4.78 million shares.
At Week 24, seralutinib showed a placebo-adjusted improvement of 13.3 meters in six-minute walk distance with a p-value of 0.0320, just missing the required threshold.
Secondary endpoints favored the drug, including a significant reduction in NT-proBNP levels, and intermediate- and high-risk patients saw a 20.0-meter placebo-adjusted improvement.
The stock has traded in a 52-week range of $0.4026 to $3.8700.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.